GlassScriptPhysician profile
Brad M Ginevan
NPI 1285732016
$14,806.44
in general payments reported to CMS, 2019-2025
60 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,160 · 2020: $1,641 · 2021: $2,459 · 2022: $2,662 · 2023: $2,661 · 2024: $2,588 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,883.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,727.77 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,511.41 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Abbvie INC. | $1,256.06 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,094.48 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Lilly USA, LLC | $884.27 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amarin Pharma, INC. | $827.52 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $681.90 | 2019-2024 | Spravato |
| Glaxosmithkline, LLC. | $606.52 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $583.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $576.42 | 2019-2024 | Verquvo, Belsomra, Steglatro |
| Scilex Pharmaceuticals INC. | $454.84 | 2022-2024 | Ztlido |
| Boehringer Ingelheim Pharmaceuticals, INC. | $347.04 | 2019-2025 | Jardiance |
| Antares Pharma, INC. | $328.70 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Axsome Therapeutics, INC. | $310.41 | 2023-2025 | Sunosi, Auvelity |
| Phathom Pharmaceuticals, INC. | $309.40 | 2024-2025 | Voquezna |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Ginevan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.